Prostate Cancer

After reviewing data from the ARASENS trial, experts consider the role of the daralutamide-containing triplet regimen in metastatic CSPC.

During a Targeted Oncology case-based roundtable event, Sheela Tejwani, MD, discussed therapy options for a patient with metastatic castration-sensitive prostate cancer.

Adam Weiner, MD, discusses the importance of molecular testing for prostate cancer and what the current targeted therapy landscape looks like for this disease.

During a live virtual event, Roby A. Thomas, MD, discussed the choice of therapy for a patient with metastatic castration-sensitive prostate cancer.

Dr Tanya Dorff presents the case of a 72-year-old man with metastatic hormone-sensitive prostate cancer.

A review of data from the ALSYMPCA clinical trial on the use of radium-223 for prostate cancer treatment.

Key opinion leaders review the case of a 72-year-old man with metastatic CSPC and consider optimal treatment approaches in this setting.

In the interview, Mark Markowski, MD, discussed how the findings from the phase 1/2 trial of sabizabulin in patients with metastatic castration-resistant prostate cancer this may influence future research with the oral agent.

During a live virtual event, Emmanuel S. Antonarakis, MD, discussed the VISION trial supporting the use of 177-lutetium-PSMA-617 for patients with metastatic castration-resistant prostate cancer. This is the second of 2 articles from this event.

Panelists center their discussion on a real-world patient case of nonmetastatic castration-resistant prostate cancer managed with surgery and adjuvant therapy.

Experts provide comprehensive insight on prostate cancer, covering its prevalence, subtypes, and the systemic treatment armamentarium.

Mark T. Fleming, MD, discusses the potential impact of positive data from the phase 3 SPOTLIGHT study, which assessed the how 18F-rhPSMA-7.3 PET scan use in male patients with biochemical recurrence of prostate cancer affects upstaging in comparison with conventional imaging.

In an interview with Targeted Oncology, Adam Weiner, MD, discussed molecular subtyping for prostate cancer based on basal and luminal cell-of-origin and how such research may impact the future of this space.

Mark Markowski, MD, PhD, discusses the design of a phase 1B/2 study of sabizabulin in men with metastatic castration-resistant prostate cancer who have had treatment and progression on an androgen receptor–targeting agent.

During a live virtual event, Emmanuel S. Antonarakis, MD, discussed the results of the CARD trial of cabazitaxel for patients with metastatic castration-resistant prostate cancer. This is part 1 of 2 articles based on this event.

Tanya Dorff, MD, reviews guidelines for initial risk stratification of patients with localized prostate cancer, and the choices in imaging strategies.

According to the phase 3 ATLAS trial, radiotherapy can be administered with next-generation hormonal therapy in phase 3 trials of patients with high-risk localized or locally advanced prostate cancer.

Reduced risk of metastatic progression and improved overall survival seen with darolutamide in patients with nonmetastatic castration-resistant prostate cancer.

Potential biomarkers of overall survival outcomes have been identified in an exploratory post-hoc analysis of the phase 3 TITAN trial.

Enzalutamide showed continued overall survival benefit in patients with metastatic hormone-sensitive prostate cancer after over 5 years of follow-up.

Richard L. Wahl, MD, discusses the approval of lutetium Lu 177 vipivotide tetraxetan for patients with prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer.

RV001 did not show superiority to placebo in terms of preventing progression of disease in patient with prostate cancer.

In an interview with Targeted Oncology, William J. Catalona, MD, reviewed the history of active surveillance in the prostate cancer space and how the practice has become more widespread in the United States.

Patients were diagnosed with prostate cancer at the expected average age with a majority of individuals diagnosed with stage 1 or 2 disease, and a significant minority presented with metastases.

In an interview with Targeted Oncology, Neal Shore, MD, FACS, discussed the use of enzalutamide plus androgen deprivation therapy in metastatic hormone sensitive prostate cancer and how post-hoc findings from the ARCHES study can be applied to practice.